Harold B. Brooks

Medicine · Health Sciences

29h-index1.9kcitations77works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Mechanisms and Therapy(12), Melanoma and MAPK Pathways(9), Cancer-related Molecular Pathways(8), Polyamine Metabolism and Applications(8), Amino Acid Enzymes and Metabolism(8)

Publications77 total

Abstract P4-12-24: Preclinical characterization of LY4045004, a next-generation, mutant-selective PI3Kα inhibitor
Clinical Cancer Research·2025
Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Abstract P142: Preclinical characterization of LOX-22783, a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor
Molecular Cancer Therapeutics·2021· 11 cited
Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models
Scientific Reports·2018· 20 citedOpen Access
Discovery of <i>N</i>-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3<i>R</i>)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model
Journal of Medicinal Chemistry·2017· 33 citedOpen Access
NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation
Scientific Reports·2016· 54 citedOpen Access
Pointwise Reconstruction of Wave Functions from Their Moments through Weighted Polynomial Expansions: An Alternative Global-Local Quantization Procedure
Mathematics·2015· 2 citedOpen Access
Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Molecular Cancer Therapeutics·2013· 115 cited
Figure 3, [– Examples of Noncompetitive Inhibition...].
2012
Figure 2: [Plateau is due to substrate depletion].
2012
Figure 5. [Initial velocity versus substrate concentration].
2012
Basics of Enzymatic Assays for HTS
2012· 35 cited
Figure 3: [Plateau is due to loss of enzyme activity (note: plateaus do not converge)].
2012
page 1 of 4Next →

Frequent Co-authors

Scott A. Watkins(12), Charles D. Spencer(12), Chuan Shih(11), Robert M. Campbell(10), Richard M. Schultz(10), Margaret A. Phillips(8), Bryan D. Anderson(8), Eileen L. Considine(8), Jack Dempsey(8), Guoxin Zhu(6), Victor L. Davidson(6), Andrei L. Osterman(5), Xun Zhou(5), Margaret M. Faul(5), Bharvin Patel(5), Faming Zhang(5), Catherine A. Ogg(5), Jeffrey R. Weidner(5), Kenneth L. Brown(5), Sandaruwan Geeganage(5)